OrbiMed Advisors LLC's Form 4 filing
Keros Therapeutics, Inc. (KROS) · filed Aug 15, 2024
- Accession no.
- 0000947871-24-000702
- Filed
- Aug 15, 2024, 5:01 PM ET
- Trade date
- Aug 13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $11.0M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| OrbiMed Advisors LLCCIK 0001055951 | Director |
| OrbiMed Capital GP VII LLCCIK 0001760648 | Director |
| OrbiMed Genesis GP LLCCIK 0001808744 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 13, 2024 | Common Stock | SSaleDisposed | −220,600 | $44.01 | −$9,708,606 | 899,212 | Indirect | Duplicate filing |
| Aug 13, 2024 | Common Stock | SSaleDisposed | −29,400 | $44.01 | −$1,293,894 | 119,522 | Indirect | Duplicate filing |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.